RecruitingPhase 3NCT04897516
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Studying American trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Principal Investigator
- María Jesús Pinazo, MDDrugs for Neglected Diseases
- Intervention
- Short regimen of benznidazole(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2021 – 2026
Study locations (6)
- Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben", Buenos Aires, Argentina
- Fundación Huésped, Buenos Aires, Argentina
- Hospital Francisco Javier Muñiz, Buenos Aires, Argentina
- Hospital Donación Francisco Santojanni, Buenos Aires, Argentina
- Instituto de Cardiología de Corrientes "Juana Francisca Cabral", Corrientes, Argentina
- Centro de Chagas y Patología Regional, Hospital Independencia, Santiago del Estero, Argentina
Collaborators
Drugs for Neglected Diseases
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04897516 on ClinicalTrials.govOther trials for American trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06632600A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Novartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07033325University-Based Chagas Testing in Salta Province, ArgentinaMundo Sano Foundation
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04984265SBRT in Chagas Disease Ventricular TachycardiaUniversity of Sao Paulo General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT04024163Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas DiseaseInsud Pharma